Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.40 |
| ▸ | FASN | P49327 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 5/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6918010 | 0.83 | GABRP (0.41) | MAOBFASNL3MBTL1MCHR1NAMPT | |
| SCHEMBL2013520 | 0.82 | TRIM33 (0.38) | MAOBFASNMCHR1NAMPTPOLQ | |
| SCHEMBL24087313 | 0.81 | NNMT (0.41) | MAOBFASNL3MBTL1DYRK1A | |
| SCHEMBL31716869 | 0.73 | GABRP (0.38) | MAOBFASNL3MBTL1DYRK1A | |
| SCHEMBL12653263 | 0.73 | DYRK1A (0.37) | MAOBFASNL3MBTL1CYP2C9DYRK1A | |
| SCHEMBL12618940 | 0.73 | DYRK1A (0.37) | MAOBFASNL3MBTL1CYP2C9DYRK1A | |
| SCHEMBL11985799 | 0.73 | L3MBTL1 (0.44) | MAOBL3MBTL1DYRK1A | |
| SCHEMBL10513798 | 0.72 | MAOB (0.32) | MAOBFASNL3MBTL1NAMPTDYRK1A | |
| SCHEMBL10513801 | 0.72 | MAOB (0.32) | MAOBFASNL3MBTL1NAMPTDYRK1A | |
| SCHEMBL407441 | 0.72 | L3MBTL1 (0.49) | L3MBTL1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2003132-B1 | Oxadiazole derivatives as S1P1 agonists | ASTELLAS PHARMA INC (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-2003132-A1 | HETERO COMPOUND | Astellas Pharma Inc. (JP) | 2008-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168159-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | MAOB 3718/4885HDAC6 3813/4885FASN 1645/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | MAOB 3718/4885HDAC6 3813/4885FASN 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.